Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.35 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.35 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.35 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.35 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.35 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.35 |
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.35 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.35 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.35 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.35 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.35 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.35 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.35 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.35 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4109608 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL28364339 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL28575502 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL3368724 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL1110550 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| Hydrochloric Acid SCHEMBL7624931 | 1.00 | LMNA (0.52) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL372614 | 0.97 | CYP2C9 (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL334182 | 0.97 | CYP2C9 (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL852253 | 0.97 | CYP2C9 (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 | |
| SCHEMBL21548014 | 0.97 | CYP2C9 (0.55) | LMNACYP2C9SLC6A2SLC6A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484867-B1 | INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2021-04-28 | — | — | EP | disclosed |
| US-10689343-B2 | Inhibitors of tryptophan 2,3-dioxygenase | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2020-06-23 | — | — | US | disclosed |
| EP-1817109-B1 | MIXED-MODAL ANION-EXCHANGE TYPE SEPARATION MATERIAL | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-20190315688-A1 | INTIBTORS OF TRYPTOPHAN 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-10-17 | — | — | US | disclosed |
| EP-3484867-A1 | INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018011227-A1 | INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-18 | — | — | WO | disclosed |
| EP-3269714-A1 | INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2018-01-17 | — | — | EP | disclosed |
| EP-2387565-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2536283-B1 | PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF | TRANSTECH PHARMA LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-9045461-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| EP-1233964-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001036417-A1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5362734-A | Certain benzo-quinolizine compounds and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| US-5225419-A | Antagonist 5-hydroxytryptamine for treatment of nausea or vomiting | JOHN WYETH & BROTHER, LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| WO-1993006108-A1 | PYRROLOBENZOXAZINE DERIVATIVES AS 5-HT AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-01 | — | — | WO | disclosed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | disclosed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | disclosed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315688-A1 | INTIBTORS OF TRYPTOPHAN 2,3-DIOXYGENASE | TPH2, TPH1, IDO2 | SLC6A2 18/4885SLC6A3 47/4885CHRM1 1004/4885 |
| US-10689343-B2 | Inhibitors of tryptophan 2,3-dioxygenase | TPH1, TPH2, IDO1 | SLC6A2 28/4885SLC6A3 43/4885CHRM1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.